Background: Ischemic heart disease (IHD) is the main cause of death in chronic kidney disease (CKD) patients with coronary atherosclerosis, which could be predicted by inflammatory biomarkers, as highly sensitive C-reactive protein (hs-CRP). IHD is linked to other independent risk factors as asymmetric dimethylarginine (ADMA) and lectin-like oxidized LDL receptor-1(LOX-1), which have proven roles in atherogenesis. Objective: To evaluate the clinical significance of ADMA and LOX-1 in addition to hs-CRP as biomarkers of IHD in end-stage renal disease (ESRD) patients with regular haemodialysis. Subjects and Methods: Patients group included 27 patients under haemodialysis with known IHD (Subgroup Ia), 13 patients under haemodialysis without IHD (Subgroup Ib), 19 patients with CKD under conservative treatment (Subgroup Ic) and a control group of 29 healthy volunteers (group II). Serum hs-CRP, ADMA, and LOX-1 were assayed. Results: The value of hs-CRP, ADMA, and LOX-1 showed a statistically significant increase in patients' group versus controls. hs-CRP and LOX-1 showed a statistically significant increase in subgroup Ia versus subgroup Ib, also between subgroup Ib and subgroup Ic. Furthermore, ADMA showed a statistically significant difference between subgroup Ia and subgroup Ic, Correlation studies in subgroup Ia between hs-CRP, ADMA and LOX-1 revealed statistically significant positive correlations. Conclusion: Serum LOX-1 is more reliable than serum ADMA in differentiating ESRD with IHD from those without IHD and its use beside hs-CRP for differentiating ESRD patients adds more strength and specification to its known predictive value.